Aadi Bioscience, Inc. (AADI)
| Market Cap | 49.54M |
| Revenue (ttm) | 23.26M |
| Net Income (ttm) | -63.41M |
| Shares Out | 24.53M |
| EPS (ttm) | -2.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 647,375 |
| Open | 2.10 |
| Previous Close | 2.10 |
| Day's Range | 2.00 - 2.12 |
| 52-Week Range | 1.90 - 13.45 |
| Beta | 0.45 |
| Analysts | Buy |
| Price Target | 5.00 (+147.53%) |
| Earnings Date | Nov 8, 2023 |
About AADI
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus bound to albumin. The company is also involved in evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is he... [Read more]
Financial Performance
In 2022, AADI's revenue was $15.22 million, an increase of 1258.57% compared to the previous year's $1.12 million. Losses were -$60.51 million, -45.35% less than in 2021.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for AADI stock is "Buy." The 12-month stock price forecast is $5.0, which is an increase of 147.53% from the latest price.
News
Top 3 Health Care Stocks That Are Preparing To Pump This Month - Durect (NASDAQ:DRRX), Aadi Bioscience (NASDAQ:AADI)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations
Interim results from investigator-assessed responses in first 40 patients from TSC1 and TSC2 arms demonstrate sustained tumor reductions in heavily pre-treated population 80 patients now enrolled in P...
Aadi Bioscience Reports Financial Results for the Third Quarter 2023 and Provides Corporate Update
PRECISION1 trial of nab-sirolimus in solid tumors with TSC1 or TSC2 inactivating alterations on track for presentation of early interim analysis by mid-December 2023; multiple 2024 catalysts expected ...
Aadi Bioscience to Participate in Jefferies London Healthcare Conference
LOS ANGELES , Nov. 6, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetica...
Aadi Bioscience to Report Third Quarter 2023 Results and Operational Update
Company to Host Conference Call and Webcast on Wednesday, November 8, 2023 LOS ANGELES , Nov. 1, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company...
Aadi Bioscience Announces Poster Presentations on Nab-Sirolimus at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting
Aadi initiates Phase 2 trial investigating the combination of nab-sirolimus with letrozole for the treatment of advanced or recurrent endometrioid-type endometrial cancer (EEC) LOS ANGELES , Oct. 19,...
Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Two new real-world next-generation sequencing studies reinforce prevalence of TSC1/2 mutations in up to 2% of all tumors, a significant addressable cancer population PRECISION1 tumor-agnostic trial te...
Aadi Bioscience Announces Poster Presentations at the North American Neuroendocrine Tumor Society (NANETS) 2023 Multidisciplinary NET Medical Symposium
LOS ANGELES , Oct. 5, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathwa...
Aadi Bioscience Grants New CEO Dave Lennon, Ph.D. Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)
LOS ANGELES , Oct. 3, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathwa...
Aadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer
Dr. Lennon brings over 20 years of pharmaceutical experience, including deep expertise in the development and commercialization of mTOR inhibitors Leadership transition expected to accelerate growth a...
Aadi Bioscience to Participate at Upcoming Investor Conferences
LOS ANGELES , Sept. 5, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined canc...
Aadi Bioscience Announces Financial Results for the Second Quarter 2023 and Provides Corporate Update
Continued growth in total revenue on FYARRO® with sales of $6.2 million for 2Q 2023 On-track for interim analysis on 40 patients in PRECISION1 trial before the end of 2023 Expanding pipeline to includ...
Aadi Bioscience to Report Second Quarter 2023 Results and Operational Update
Company to Host Conference Call and Webcast on Wednesday, August 9, 2023 LOS ANGELES , Aug. 2, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company f...
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This MonthSilk Road Me
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Aadi Bioscience Announces Presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
LOS ANGELES , May 25, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetica...
Aadi Bioscience to Participate in Upcoming Investor Events
LOS ANGELES, May 23, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetical...
Aadi Bioscience Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial
Total 1Q 2023 revenue on FYARRO® sales of $5.9 million PRECISION 1 tumor agnostic trial enrolling equally in TSC1 and TSC2 arms with more than 15 discreet tumor types represented Interim analysis on 4...
Aadi Bioscience to Report First Quarter 2023 Results and Operational Update
Company to Host Conference Call and Webcast on Wednesday, May 10, 2023 LOS ANGELES , May 3, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focu...
Aadi Bioscience Announces Multiple Presentations on nab-Sirolimus at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
LOS ANGELES , April 26, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for geneti...
Aadi Bioscience to Present Multiple Posters on nab-Sirolimus at the 2023 American Association for Cancer Research (AACR) Annual Meeting
LOS ANGELES , April 14, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for geneti...
Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2023
LOS ANGELES , April 6, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetic...
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Corporate Update
Total revenue on FYARRO® sales of $15.2 million for FY 2022 PRECISION 1 trial preliminary data expected in the second quarter of 2023 Conference call to be held today at 8:30 am EDT LOS ANGELES , Marc...
Aadi Bioscience Appoints Mohammad Hirmand, M.D. to Board of Directors
LOS ANGELES , March 27, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for geneti...
Aadi Bioscience Presents Clinical Data from PRECISION 1 and AMPECT Trials at the Society of Gynecological Oncology (SGO) Annual Meeting on Women's Cancer
LOS ANGELES , March 26, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for geneti...
Aadi Bioscience to Report Fourth Quarter and Full-Year 2022 Results and Corporate Update
Company to Host Conference Call and Webcast on March 28, 2023 LOS ANGELES , March 15, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on...